From: Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases
EVs or cargo in EVs | Source | Isolation method | Quantification method | Biomarkers | References |
---|---|---|---|---|---|
MiR-4484 | Saliva | Precipitation | MiRNA microarray analysis and flow cytometry | OLP | [45] |
MiR-34a-5p, miR-130b-3p and miR-301b-3p | Plasma | Membrane affinity -based capture | MiRNA microarray analysis and flow cytometry | OLP | [49] |
Hcmv-miR-UL59 | Plasma | Precipitation | RT-qPCR analysis | OLP | [48] |
Total MPs, CD14 + MPs, Granulocytes-derived MPs, and tissue factor + MPs | Plasma | Affinity-based capture | Flow cytometry | BS | [59] |
PMPs | Whole blood | Unreported | Flow cytometry | BS | [60] |
Procoagulant MPs | Plasma | Affinity-based capture | Functional prothrombinase capture assay | BS | [61] |
MiR-16-5p, miR-574-5p and miR-302d-3p | Plasma | Ultracentrifugation | RT-qPCR analysis | T1DM | [62] |
Insulin-containing exosomes, exosomal islet autoantigen and GAD65 | Plasma | Size-based filtration | Affinity-based capture and RT-PCR analyses | T1DM | [63] |